(Q36383775)

13 August 2017

1 reference

title

Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women (English)

1 reference

13 August 2017

1 reference

coronary artery disease

1 reference

inferred from title

author name string

Tatjana Elène Vogelvang

1

1 reference

13 August 2017

Marius Jan van der Mooren

2

1 reference

13 August 2017

Velja Mijatovic

3

1 reference

13 August 2017

Peter Kenemans

4

1 reference

13 August 2017

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

66

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

191-221

1 reference

Menopause and risk of cardiovascular disease: the Framingham study.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

Lipoprotein(a) and Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

Hormone therapy to prevent disease and prolong life in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

Tamoxifen reduces plasma homocysteine levels in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666020-00005

Effects of raloxifene therapy on the anticoagulant system in postmenopausal women

21 January 2018

1 reference

12 December 2020

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

1 reference

12 December 2020

Tamoxifen for breast cancer among hysterectomised women

1 reference

12 December 2020

A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine

1 reference

12 December 2020

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

12 December 2020

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

1 reference

12 December 2020

Hormone therapy and venous thromboembolism

1 reference

12 December 2020

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

12 December 2020

Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial

1 reference

12 December 2020

Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.

1 reference

12 December 2020

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

12 December 2020

Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors

1 reference

12 December 2020

Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal

1 reference

12 December 2020

Menopause-induced changes in left ventricular wall thickness

1 reference

12 December 2020

Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women

1 reference

12 December 2020

A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits

1 reference

12 December 2020

HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women

1 reference

12 December 2020

The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial

1 reference

12 December 2020

Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects.

1 reference

12 December 2020

LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo

1 reference

12 December 2020

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

1 reference

12 December 2020

Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats

1 reference

12 December 2020

Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.

1 reference

12 December 2020

Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women

1 reference

12 December 2020

The effects of hormone replacement therapy on echocardiographic basic cardiac functions in postmenopausal women

1 reference

12 December 2020

Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.

1 reference

12 December 2020

Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women

1 reference

12 December 2020

Hormone replacement therapy, heart disease, and other considerations

1 reference

12 December 2020

Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens

1 reference

12 December 2020

1 reference

12 December 2020

Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer

1 reference

12 December 2020

Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment

1 reference

12 December 2020

Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies

1 reference

12 December 2020

Antithrombin III Level, Fibrinogen Level, and Platelet Count Changes With Adjuvant Tamoxifen Therapy

1 reference

12 December 2020

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women

1 reference

12 December 2020

Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

1 reference

12 December 2020

Coronary heart disease mortality and adjuvant tamoxifen therapy

1 reference

12 December 2020

Is there a menopausal metabolic syndrome?

1 reference

12 December 2020

A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

12 December 2020

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

12 December 2020

Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels

1 reference

12 December 2020

Primary prevention of coronary heart disease in women through diet and lifestyle

1 reference

12 December 2020

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

12 December 2020

Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene

1 reference

12 December 2020

Preclinical data for Droloxifene

1 reference

12 December 2020

Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life

1 reference

12 December 2020

Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI)

1 reference

12 December 2020

Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women

1 reference

12 December 2020

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats

1 reference

12 December 2020

Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats

1 reference

12 December 2020

Design and methods of the Raloxifene Use for The Heart (RUTH) study

1 reference

12 December 2020

Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study

1 reference

12 December 2020

Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications

1 reference

12 December 2020

Long-term effects of hormone replacement therapy on Doppler-derived parameters of aortic flow in postmenopausal women

1 reference

12 December 2020

Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.

1 reference

12 December 2020

Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen

1 reference

12 December 2020

Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function

1 reference

12 December 2020

Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene

1 reference

12 December 2020

Estrogen plus progestin and the risk of coronary heart disease

1 reference

12 December 2020

Plasma TAFI antigen variations in healthy subjects

1 reference

12 December 2020

A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats

1 reference

12 December 2020

Cardiovascular responses of perimenopausal women to hormonal replacement therapy

1 reference

12 December 2020

Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women

1 reference

12 December 2020

Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women

1 reference

12 December 2020

Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

1 reference

12 December 2020

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

1 reference

12 December 2020

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

12 December 2020

Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women

1 reference

12 December 2020

Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women

1 reference

12 December 2020

Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats

1 reference

12 December 2020

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

12 December 2020

Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial

1 reference

12 December 2020

Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator

1 reference

12 December 2020

Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy

1 reference

12 December 2020

Estrogen and coronary heart disease in women

1 reference

12 December 2020

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

1 reference

12 December 2020

Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene

1 reference

12 December 2020

Molecular basis of agonism and antagonism in the oestrogen receptor

1 reference

12 December 2020

Effects of 15 months of 17 beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women

1 reference

12 December 2020

Effect of tamoxifen on measurements of hemostasis in healthy women

1 reference

12 December 2020

Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis

1 reference

12 December 2020

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

12 December 2020

Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors

1 reference

12 December 2020

Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules

1 reference

12 December 2020

Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women

1 reference

12 December 2020

Effect of tamoxifen on fibrinogen, D-dimer, lipid and lipoprotein concentrations in breast cancer patients

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women

1 reference

12 December 2020

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study

1 reference

12 December 2020

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection

1 reference

12 December 2020

Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis

1 reference

12 December 2020

Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer

1 reference

12 December 2020

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

12 December 2020

Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group

1 reference

12 December 2020

Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen

1 reference

12 December 2020

Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene

1 reference

12 December 2020

Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

1 reference

12 December 2020

Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.

1 reference

12 December 2020

Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein.

1 reference

12 December 2020

A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.

1 reference

12 December 2020

A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor

1 reference

12 December 2020

Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women

1 reference

12 December 2020

Overview of the main outcomes in breast-cancer prevention trials

1 reference

12 December 2020

Fibrinogen and risk of cardiovascular disease. The Framingham Study.

1 reference

12 December 2020

Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer

1 reference

12 December 2020

Lack of effect of estrogen on rest and treadmill exercise in postmenopausal women without known cardiac disease

1 reference

12 December 2020

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

12 December 2020

Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial.

1 reference

12 December 2020

Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models

1 reference

12 December 2020

1 reference

12 December 2020

Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice

1 reference

12 December 2020

Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma

1 reference

12 December 2020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

Homocysteine in postmenopausal women and the importance of hormone replacement therapy

1 reference

12 December 2020

Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat

1 reference

12 December 2020

Folate and Vitamin B 6 From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women

1 reference

12 December 2020

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

1 reference

12 December 2020

Effects of a single dose of oral estrogen on left ventricular diastolic function in hypertensive postmenopausal women with diastolic dysfunction.

1 reference

12 December 2020

Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats

1 reference

12 December 2020

Uterine sarcoma associated with tamoxifen use.

1 reference

12 December 2020

Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women

1 reference

12 December 2020

Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women

1 reference

12 December 2020

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

12 December 2020

High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment

1 reference

12 December 2020

Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

1 reference

12 December 2020

The effect of different doses of micronized 17beta-estradiol on C-reactive protein, interleukin-6, and lipids in older women

1 reference

12 December 2020

The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women

1 reference

12 December 2020

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

1 reference

12 December 2020

Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens

1 reference

12 December 2020

LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34)

1 reference

12 December 2020

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N

1 reference

12 December 2020

A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

1 reference

12 December 2020

Left ventricular diastolic function by Doppler echocardiography in relation to hormonal replacement therapy in healthy postmenopausal women

1 reference

12 December 2020

Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Idoxifene: report of a phase I study in patients with metastatic breast cancer

1 reference

12 December 2020

Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis

1 reference

12 December 2020

The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells

1 reference

12 December 2020

Plasma procarboxypeptidase U in men with symptomatic coronary artery disease

1 reference

12 December 2020

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer

1 reference

12 December 2020

Influence of tamoxifen on carotid intima-media thickness in postmenopausal women

1 reference

12 December 2020

Increased plasma homocysteine after menopause

1 reference

12 December 2020

Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia

1 reference

12 December 2020

Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.

1 reference

12 December 2020

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

12 December 2020

Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat

1 reference

12 December 2020

HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women

1 reference

12 December 2020

Lipoprotein (a) and coronary heart disease.

1 reference

12 December 2020

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

1 reference

12 December 2020

The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow

1 reference

12 December 2020

Phase I trial of droloxifene in patients with metastatic breast cancer.

1 reference

12 December 2020

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

1 reference

12 December 2020

Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.

1 reference

12 December 2020

Plasma homocysteine and menopausal status.

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Women and heart disease.

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.2165/00003495-200666020-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1002468960

0 references

1 reference